Secukinumab for the treatment of generalized pustular psoriasis: A case report
Sign Up to like & getrecommendations! Published in 2023 at "Medicine"
DOI: 10.1097/md.0000000000033693
Abstract: Introduction: Generalized pustular psoriasis (GPP) is a rare subtype of psoriasis that manifests as a generalized pustular eruption. Patient concerns: A 31-year-old female was admitted to the hospital in June 2021 with a widespread erythematous,… read more here.
Keywords: secukinumab treatment; generalized pustular; treatment generalized; pustular psoriasis ... See more keywords
Secukinumab treatment and vaccination efficacy.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical and experimental dermatology"
DOI: 10.1111/ced.15004
Abstract: Dear Editor, Secukinumab, a monoclonal antibody against interleukin (IL)-17A, is used to treat psoriasis and psoriatic arthritis. The effect of this treatment on COVID-19 vaccination is not well characterized. While IL-17 deficiency states are associated… read more here.
Keywords: dermatology; vaccination efficacy; treatment; secukinumab treatment ... See more keywords
Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
Sign Up to like & getrecommendations! Published in 2019 at "Case Reports in Dermatology"
DOI: 10.1159/000501993
Abstract: Although available data are conflicting, psoriasis seems to be associated with an increased baseline risk of malignancy. In addition, some antipsoriatic systemic treatments have been associated with risk of malignancy. There is not enough data… read more here.
Keywords: secukinumab treatment; malignancy; psoriasis; plaque psoriasis ... See more keywords
Secukinumab in the treatment of psoriasis: patient selection and perspectives
Sign Up to like & getrecommendations! Published in 2018 at "Psoriasis: Targets and Therapy"
DOI: 10.2147/ptt.s146004
Abstract: Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In Phase III clinical trials for each of these three indications, secukinumab… read more here.
Keywords: patient selection; secukinumab treatment; selection; psoriasis ... See more keywords
Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review.
Sign Up to like & getrecommendations! Published in 2022 at "Immunotherapy"
DOI: 10.2217/imt-2021-0128
Abstract: Background/aim: Multiple sclerosis (MS) is a demyelinating central nervous system disorder with few cases reported to have concomitant spondyloarthritis (SpA) spectrum disorders such as ankylosing spondylitis and psoriatic arthritis. The aim of this study is… read more here.
Keywords: treatment; multiple sclerosis; psoriatic arthritis; secukinumab treatment ... See more keywords
Lichen planus associated with secukinumab treatment for plaque psoriasis.
Sign Up to like & getrecommendations! Published in 2023 at "Dermatology online journal"
DOI: 10.5070/d329260779
Abstract: Secukinumab and ixekizumab are IL17A inhibitors most commonly used to treat psoriasis. Common side effects include upper respiratory tract infections, injection site reactions, and mucocutaneous candidiasis. Recently, these medications have been reported to trigger lichen… read more here.
Keywords: psoriasis; secukinumab treatment; lichen planus;